FDA Adverse Event Malfunction Summary report: N

MINIMALLY INVASIVE DEFORMITY CORRECTION (MID-C) SYSTEM

MDR report key: 19687945 · Received July 8, 2024

Report

Report Number
3013461531-2024-00027
Event Type
Malfunction
Date Received
July 8, 2024
Date of Event
May 31, 2024
Report Date
January 27, 2025
Manufacturer
APIFIX LTD.
Product Code
QGP
UDI-DI
07290018128046
PMA / PMN Number
H170001
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
FL, US
Reporter Occupation
OTHER
Health Professional
N

Narratives

Additional Manufacturer Narrative · 0

ON (B)(6) 2024 APIFIX WAS NOTIFIED THAT PATIENT #(B)(6) UNDERWENT REMOVAL SURGERY ON (B)(6) 2024. DEVICE IS EXPECTED TO BE RETURNED FOR ANALYSIS. ONCE ADDITIONAL RELEVANT DETAILS BECOME AVAILABLE; A SUPPLEMENTAL REPORT WILL BE SUBMITTED.

Additional Manufacturer Narrative · 0

CORRECTION: BRAND NAME [D1] OF THE DEVICE WAS INCORRECTLY SUBMITTED IN THE INITIAL REPORT; BRAND NAME HAS BEEN CORRECTED IN THIS REPORT TO 'MINIMALLY INVASIVE DEFORMITY CORRECTION (MID-C) SYSTEM'. ADDITIONAL INFORMATION / DEVICE EVALUATION THE EXPLANTED DEVICE WAS RETURNED, AND WAS SUBJECTED TO CLEANING, STEAM STERILIZING, AND ENGINEERING EVALUATION. THE DEVICE WAS OBVIOUSLY FRACTURED IN THE POLE COMPONENT AROUND THE MID-POINT OF THE POLE. THE FRACTURE PLANE WAS WORN SMOOTH AND THUS FRACTURE MODE IS NOT ABLE TO BE IDENTIFIED. THE SPHERICAL RINGS WERE INSPECTED FOR WEAR. NO WEAR WAS VISIBLY OBSERVED ON THE SPHERICAL RINGS. OVER THE YEARS, THE COMPANY ALREADY IMPLEMENTED CORRECTIVE ACTION WITH THE FOLLOWING: ON NOV 2017, ALL SURGEONS RECEIVED A LETTER DETAILING THE IMPORTANCE OF SCREW INSERTION TRAJECTORY. THE TOPIC IS ALSO COVERED IN THE COMPANY'S TRAINING PRESENTATION. ECO-38 (APPROVED IN H170001/S002): REPLACED THE MID-C 125 THAT EXTENDS BY 40 MM TO MID-C 125 THAT EXTENDS BY 50MM ALLOWING MORE OVERLAP BETWEEN THE POLE AND BASE. ECO-46 (APPROVED IN H170001/S002): A TRIAL TOOL ADDED TO THE SURGICAL TOOLS TO AID THE SURGEON IN DETECTING IF ACCESS TISSUE REMAINS BELOW THE IMPLANT. ON MARCH 2020, THE TOPIC OF PRACTICING SEVERE SPORTS ADDED TO THE MID-C TRAINING PRESENTATION. A PRECAUTION ABOUT SEVERE SPORTS WAS INCLUDED IN THE IFU APPROVED IN H170001. ON OCTOBER 2020, AS PART OF APIFIX COMMITMENT TO CONTINUOUS IMPROVEMENT, CAPA#: 020-01 WAS INITIATED TO FURTHER INVESTIGATE TO PREVENT AND MINIMIZE THE RATE OF IMPLANT BREAKAGE. ECO-13264 (APPROVED IN H170001/S015): INCREASE STRENGTH THROUGH: DECREASE STRESS CONCENTRATIONS AND INCREASE CROSS SECTIONAL AREA AT CRITICAL REGIONS.

Additional Manufacturer Narrative · 0

INVESTIGATION: A REVIEW OF THE DEVICE HISTORY RECORD CONFIRMED THAT THE DEVICE WAS MANUFACTURED AND TESTED ACCORDING TO RELEVANT PROCEDURES,AND SHIPPED ACCORDING TO MANUFACTURER'S SPECIFICATIONS. SURGEON, INFORMATION ANALYSIS: PATIENT # (B)(6) (PAS #(B)(6)) INDEX SURGERY WAS PERFORMED ON (B)(6) 2021. AT THE PATIENT'S ONE YEAR FOLLOW-UP XRAY IMAGES EXHIBITED A BROKEN ROD. [REF: MDR: 3013461531-2022-00039] ON (B)(6) 2022 THE PATIENT WAS REVISED. THE OP SCREWS ORIGINALLY AT T5&T6 STAYED IN, AND THE SURGEON ADDED AN OP SCREW AT T7. A NEW MID-C 125 AND EXTENDER WERE USED. THEY KEPT THE ORIGINAL APIFIX SCREW, BUT OPENED A NEW NUT. CALIPER MEASURED 135°, AND KITE ANGLE: 10°. [DURING THE REVISION, SURGEON ADDED A THIRD POLYAXIAL SCREW. USE OF THREE (3) SCREWS IS NOT PER THE SUGICAL TECHNIQUE OR IFU. APIFIX INSTRUCTS THE USE OF TWO POLYAXIAL SCREWS ONLY. WHEN USING THREE SCREWS THE EXTENDER JOINT HAS LESS RANGE OF MOTION AND IS MORE PRONE TO BREAKAGE.] ON (B)(6) 2024 DURING MONITORING OF THE PAS, APIFIX IDENTIFIED THAT PATIENT # (B)(6) (PAS# (B)(6)) VISITED THE CLINIC ON (B)(6) 2024 WHERE THE PATIENT REPORTEDLY HAD 'AGGRAVATION OF A POST-OP CONDITION', SPECIFICALLY 'INCREASING CREPITANCE AND DISCOMFORT OVER DISTAL SCREW, IMPLANT APPEARS TO BE FRACTURED AT THE JUNCTION OF THE RATCHET AND SMOOTH ROD. NO SIGNIFICANT CHANGE FROM PRIOR X-RAY. NO DISLODGMENT. THE DEVICE IS FULLY LENGTHENED. RESIDUAL MAIN CURVE 35° (50° PRIOR TO REVISION SURGERY), ADEQUATE BALANCE.' CONVERSION TO DEFINITIVE POSTERIOR SPINAL FUSION, THE EXPECTED PROCEDURE AND POST-OP COURSE WERE DISCUSSED WITH THE PATIENT AND THE FAMILY DURING THE CLINIC VISIT. THE APPROPRIATE RISKS, BENEFITS, AND ALTERNATIVES WERE REVIEWED. PATIENT *AND FAMILY WISH TO PROCEED. SPINAL FUSION SCHEDULED FOR (B)(6) 2024. RISK ASSESSMENT: REOPERATION EVENTS ARE A KNOWN RISK THAT WAS ASSESSED AND RECORDED BY THE PRODUCT RISK ASSESSMENT. IMPLANT BREAKAGE IS ADDRESSED IN THE IFU AS POTENTIAL RISKS ASSOCIATED WITH THE MID-C SYSTEM AND SPINAL SURGERY GENERALLY. THE RISK OF BROKEN ROD - IMPLANT BREAKAGE HAS BEEN ASSESSED AND FOUND TO BE ACCEPTABLE. THE RISK HAS BEEN QUANTIFIED, CHARACTERIZED, AND DOCUMENTED AS ACCEPTABLE WITHIN FULL RISK ASSESSMENT. THE SUBJECT DEVICE IS EXPECTED TO BE RETURNED TO MANUFACTURER FOLLOWING THE REMOVAL IN (B)(6) 2024. A FAILURE ANALYSIS WILL BE CONDUCTED. ONCE ADDITIONAL RELEVANT DETAILS BECOME AVAILABLE; A SUPPLEMENTAL REPORT WILL BE SUBMITTED.

Description of Event or Problem · 0

ON 16-JUN-2024 DURING MONITORING OF THE PAS, APIFIX IDENTIFIED THAT PATIENT # (B)(6) (PAS# (B)(6)) VISITED THE CLINIC ON (B)(6) 2024 WHERE THE PATIENT REPORTEDLY HAD 'AGGRAVATION OF A POST-OP CONDITION', SPECIFICALLY 'INCREASING CREPITANCE AND DISCOMFORT OVER DISTAL SCREW, IMPLANT APPEARS TO BE FRACTURED AT THE JUNCTION OF THE RATCHET AND SMOOTH ROD. NO SIGNIFICANT CHANGE FROM PRIOR X-RAY. NO DISLODGMENT. THE DEVICE IS FULLY LENGTHENED. RESIDUAL MAIN CURVE 35° (50° PRIOR TO REVISION SURGERY), ADEQUATE BALANCE.' CONVERSION TO DEFINITIVE POSTERIOR SPINAL FUSION, THE EXPECTED PROCEDURE AND POST-OP COURSE WERE DISCUSSED WITH THE PATIENT AND THE FAMILY DURING THE CLINIC VISIT. THE APPROPRIATE RISKS, BENEFITS, AND ALTERNATIVES WERE REVIEWED. PATIENT *AND FAMILY WISH TO PROCEED. SPINAL FUSION SCHEDULED FOR (B)(6) 2024.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
143034 MINIMALLY INVASIVE DEFORMITY CORRECTION (MID-C) SYSTEM POSTERIOR RATCHETING ROD SYSTEM QGP APIFIX LTD. MID-C 125 AF-03-080-21 07290018128046

Patients

Seq Age Sex Outcome Treatment
1 16 YR Male